Prevalence of rotavirus infection in pediatric patients after introduction of the Rotateq@ vaccine in Jordan

Abstract

Rotavirus is the leading causative agent of acute gastroenteritis in children. Rotateq@ vaccine is one of the recommended rotavirus vaccines by WHO, which been approved in 2007. Jordan has introduced the Rotateq@ into the national vaccination program in 2015. This study aims to assess the impact of introducing the Rotateq@ on the prevalence of rotavirus infection in Jordan. A total of 191 stool samples were collected from patients under 5 years of age whom were admitted to the military Jordanian hospitals with symptoms of gastroenteritis associated with diarrhea. RT-PCR assays were carried out to detect the VP7 and VP4 genes of Rotavirus. An assay targeting the distinctive vaccine gene “NSP3” was also conducted to discriminate between wild and vaccine infection. Sequence analysis was applied to the VP7 and VP4 genes of positive rotavirus samples to confirm the results and identify the genotypes. The results showed that 11 samples out of 191 (<6%) were confirmed as rotavirus infection. No vaccine strains were detected in any of the samples. Sequence analysis for VP7 and VP4 genes identified the genotypes as G1P8 (36%), G2P4 (36%), G1NA (18%), and G2NA (9%). This study revealed the significant impact of the Rotateq@ vaccine in reducing the prevalence of rotavirus infection within the target population in Jordan.

References

  • 2013. Rotavirus vaccines WHO position paper: January 2013 - Recommendations. Vaccine 31:6170-6171.
  • Armah GE, et al. 2010. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 376:606-614.
  • Banyai K, Laszlo B, Duque J, Steele AD, Nelson EA, Gentsch JR, Parashar UD. 2012. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine 30 Suppl 1:A122-130.
  • Burnett E, Jonesteller CL, Tate JE, Yen C, Parashar UD. 2017. Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality From Diarrhea. J Infect Dis 215:1666-1672.
  • Chandran A, Santosham M. 2008. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine. Expert Rev Vaccines 7:1475-1480.
  • Chavers T, De Oliveira LH, Parashar UD, Tate JE. 2018. Post-licensure experience with rotavirus vaccination in Latin America and the Caribbean: a systematic review and meta-analysis. Expert Rev Vaccines 17:1037-1051.
  • Crawford SE, et al. 2017. Rotavirus infection. Nat Rev Dis Primers 3:17083.
  • Doan YH, Nakagomi T, Cunliffe NA, Pandey BD, Sherchand JB, Nakagomi O. 2011. The occurrence of amino acid substitutions D96N and S242N in VP7 of emergent G2P[4] rotaviruses in Nepal in 2004-2005: a global and evolutionary perspective. Arch Virol 156:1969-1978.
  • Donato CM, Zhang ZA, Donker NC, Kirkwood CD. 2014. Characterization of G2P[4] rotavirus strains associated with increased detection in Australian states using the RotaTeq(R) vaccine during the 2010-2011 surveillance period. Infect Genet Evol 28:398-412.
  • Esposito S, Camilloni B, Bianchini S, Ianiro G, Polinori I, Farinelli E, Monini M, Principi N. 2019. First detection of a reassortant G3P[8] rotavirus A strain in Italy: a case report in an 8-year-old child. Virol J 16:64.
  • Gentsch JR, Glass RI, Woods P, Gouvea V, Gorziglia M, Flores J, Das BK, Bhan MK. 1992. Identification of group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol 30:1365-1373.
  • Gouvea V, Glass RI, Woods P, Taniguchi K, Clark HF, Forrester B, Fang ZY. 1990. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. J Clin Microbiol 28:276-282.
  • Gurgel RQ, Alvarez Ade J, Rodrigues A, Ribeiro RR, Dolabella SS, Da Mota NL, Santos VS, Iturriza-Gomara M, Cunliffe NA, Cuevas LE. 2014. Incidence of rotavirus and circulating genotypes in Northeast Brazil during 7 years of national rotavirus vaccination. PLoS One 9:e110217.
  • Jeong S, Than VT, Lim I, Kim W. 2016. Differentiation of RotaTeq((R)) vaccine strains from wild-type strains using NSP3 gene in reverse transcription polymerase chain reaction assay. J Virol Methods 237:72-78.
  • Kaneko M, Takanashi S, Thongprachum A, Hanaoka N, Fujimoto T, Nagasawa K, Kimura H, Okitsu S, Mizuguchi M, Ushijima H. 2017. Identification of vaccine-derived rotavirus strains in children with acute gastroenteritis in Japan, 2012-2015. PLoS One 12:e0184067.
  • Kaplan NM, Kirby A, Abd-Eldayem SA, Dove W, Nakagomi T, Nakagomi O, Cunliffe NA. 2011. Detection and molecular characterisation of rotavirus and norovirus infections in Jordanian children with acute gastroenteritis. Arch Virol 156:1477-1480.
  • Keating GM. 2006. Rotavirus vaccine (RotaTeq). Paediatr Drugs 8:197-202; discussion 203-194.
  • Khuri-Bulos N, Al Khatib M. 2006. Importance of rotavirus as a cause of gastroenteritis in Jordan: a hospital based study. Scand J Infect Dis 38:639-644.
  • Kirkwood CD, Boniface K, Barnes GL, Bishop RF. 2011. Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix(R) and RotaTeq(R), into the National Immunization Program of Australia. Pediatr Infect Dis J 30:S48-53.
  • Kirkwood CD, Ma LF, Carey ME, Steele AD. 2019. The rotavirus vaccine development pipeline. Vaccine 37:7328-7335.
  • Markkula J, Hemming M, Vesikari T. 2015. Detection of vaccine-derived rotavirus strains in nonimmunocompromised children up to 3-6 months after RotaTeq(R) vaccination. Pediatr Infect Dis J 34:296-298.
  • Muendo C, Laving A, Kumar R, Osano B, Egondi T, Njuguna P. 2018. Prevalence of rotavirus infection among children with acute diarrhoea after rotavirus vaccine introduction in Kenya, a hospital cross-sectional study. BMC Pediatr 18:323.
  • Mwenda JM, Mandomando I, Jere KC, Cunliffe NA, Duncan Steele A. 2019. Evidence of reduction of rotavirus diarrheal disease after rotavirus vaccine introduction in national immunization programs in the African countries: Report of the 11(th) African rotavirus symposium held in Lilongwe, Malawi. Vaccine 37:2975-2981.
  • Nafi O. 2010. Rotavirus gastroenteritis among children aged under 5 years in Al Karak, Jordan. East Mediterr Health J 16:1064-1069.
  • Offit PA, Clark HF. 2006. RotaTeq: a pentavalent bovine--human reassortant rotavirus vaccine. Pediatr Ann 35:29-34.
  • Payne DC, Edwards KM, Bowen MD, Keckley E, Peters J, Esona MD, Teel EN, Kent D, Parashar UD, Gentsch JR. 2010. Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics 125:e438-441.
  • Payne DC, et al. 2019. Association of Rotavirus Vaccination With Inpatient and Emergency Department Visits Among Children Seeking Care for Acute Gastroenteritis, 2010-2016. JAMA Netw Open 2:e1912242.
  • Plosker GL. 2010. Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe. Drugs 70:1165-1188.
  • Roczo-Farkas S, Kirkwood CD, Cowley D, Barnes GL, Bishop RF, Bogdanovic-Sakran N, Boniface K, Donato CM, Bines JE. 2018. The Impact of Rotavirus Vaccines on Genotype Diversity: A Comprehensive Analysis of 2 Decades of Australian Surveillance Data. J Infect Dis 218:546-554.
  • Salem K, Bdour S, Zeller M, Van Ranst M, Matthijnssens J. 2011. Genotypes of rotavirus strains circulating in Amman, Jordan, in 2006/07 and their significance for the potential effectiveness of future rotavirus vaccination. Arch Virol 156:1543-1550.
  • Thanh HD, Tran VT, Lim I, Kim W. 2018. Emergence of Human G2P[4] Rotaviruses in the Post-vaccination Era in South Korea: Footprints of Multiple Interspecies Re-assortment Events. Sci Rep 8:6011.
  • Vesikari T, et al. 2006. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354:23-33.
  • Vizzi E, Pineros OA, Oropeza MD, Naranjo L, Suarez JA, Fernandez R, Zambrano JL, Celis A, Liprandi F. 2017. Human rotavirus strains circulating in Venezuela after vaccine introduction: predominance of G2P[4] and reemergence of G1P[8]. Virol J 14:58.
  • Zeller M, et al. 2015. Emerging OP354-Like P[8] Rotaviruses Have Rapidly Dispersed from Asia to Other Continents. Mol Biol Evol 32:2060-2071.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.